Mizuho Securities Co. Ltd. Cuts Stock Holdings in Johnson & Johnson (NYSE:JNJ)

Mizuho Securities Co. Ltd. lowered its stake in shares of Johnson & Johnson (NYSE:JNJ – Get Rating) by 24.7% during the third quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 1,555 shares of the company’s stock after selling 509 shares during the period. Mizuho Securities Co. Ltd.’s holdings in Johnson & Johnson were worth $254,000 at the end of the most recent reporting period.

A number of other large investors also recently bought and sold shares of the stock. RKL Wealth Management LLC raised its stake in shares of Johnson & Johnson by 2.1% in the 2nd quarter. RKL Wealth Management LLC now owns 48,233 shares of the company’s stock valued at $8,562,000 after acquiring an additional 1,010 shares during the period. Geller Advisors LLC grew its holdings in Johnson & Johnson by 7.5% during the 2nd quarter. Geller Advisors LLC now owns 9,260 shares of the company’s stock valued at $1,644,000 after purchasing an additional 648 shares in the last quarter. Simon Quick Advisors LLC grew its holdings in Johnson & Johnson by 296.9% during the 2nd quarter. Simon Quick Advisors LLC now owns 8,739 shares of the company’s stock valued at $1,495,000 after purchasing an additional 6,537 shares in the last quarter. Lokken Investment Group LLC grew its holdings in Johnson & Johnson by 1.6% during the 2nd quarter. Lokken Investment Group LLC now owns 12,968 shares of the company’s stock valued at $2,302,000 after purchasing an additional 201 shares in the last quarter. Finally, Keebeck Alpha LP grew its holdings in Johnson & Johnson by 13.4% during the 2nd quarter. Keebeck Alpha LP now owns 4,442 shares of the company’s stock valued at $788,000 after purchasing an additional 525 shares in the last quarter. Hedge funds and other institutional investors own 67.94% of the company’s stock.

Johnson & Johnson Stock Performance

NYSE JNJ opened at $168.31 on Wednesday. Johnson & Johnson has a one year low of $155.72 and a one year high of $186.69. The company has a 50-day simple moving average of $175.98 and a 200-day simple moving average of $171.06. The company has a debt-to-equity ratio of 0.37, a quick ratio of 1.18 and a current ratio of 1.43. The firm has a market capitalization of $440.04 billion, a PE ratio of 23.44, a price-to-earnings-growth ratio of 3.21 and a beta of 0.56.

Johnson & Johnson (NYSE:JNJ – Get Rating) last issued its quarterly earnings data on Tuesday, January 24th. The company reported $2.35 earnings per share for the quarter, beating the consensus estimate of $2.23 by $0.12. The firm had revenue of $23.71 billion for the quarter, compared to the consensus estimate of $23.90 billion. Johnson & Johnson had a net margin of 19.95% and a return on equity of 35.37%. Johnson & Johnson’s quarterly revenue was down 4.4% compared to the same quarter last year. During the same period last year, the firm posted $2.13 EPS. On average, equities analysts forecast that Johnson & Johnson will post 10.04 earnings per share for the current year.

Johnson & Johnson Dividend Announcement

The company also recently disclosed a quarterly dividend, which will be paid on Tuesday, March 7th. Investors of record on Tuesday, February 21st will be given a $1.13 dividend. The ex-dividend date is Friday, February 17th. This represents a $4.52 annualized dividend and a yield of 2.69%. Johnson & Johnson’s dividend payout ratio is presently 62.95%.

Insider Activity at Johnson & Johnson

In related news, CFO Joseph J. Wolk sold 14,781 shares of Johnson & Johnson stock in a transaction dated Tuesday, December 13th. The shares were sold at an average price of $179.60, for a total value of $2,654,667.60. Following the sale, the chief financial officer now directly owns 35,812 shares in the company, valued at approximately $6,431,835.20. The sale was disclosed in a legal filing with the SEC, which is available at the SEC website. In other Johnson & Johnson news, CAO Robert J. Decker sold 16,928 shares of the business’s stock in a transaction dated Friday, November 18th. The shares were sold at an average price of $175.00, for a total transaction of $2,962,400.00. Following the sale, the chief accounting officer now directly owns 15,473 shares in the company, valued at approximately $2,707,775. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this link. Also, CFO Joseph J. Wolk sold 14,781 shares of the business’s stock in a transaction dated Tuesday, December 13th. The stock was sold at an average price of $179.60, for a total transaction of $2,654,667.60. Following the sale, the chief financial officer now owns 35,812 shares in the company, valued at $6,431,835.20. The disclosure for this sale can be found here. Insiders have sold a total of 233,611 shares of company stock worth $40,960,735 in the last ninety days. 0.35% of the stock is owned by insiders.

Analyst Ratings Changes

A number of research firms recently weighed in on JNJ. StockNews.com began coverage on shares of Johnson & Johnson in a report on Wednesday, October 12th. They set a “strong-buy” rating for the company. Credit Suisse Group initiated coverage on shares of Johnson & Johnson in a report on Thursday, November 17th. They set a “neutral” rating and a $170.00 price target for the company. Citigroup raised their price objective on shares of Johnson & Johnson from $198.00 to $205.00 and gave the stock a “buy” rating in a report on Monday, December 12th. Atlantic Securities decreased their price objective on shares of Johnson & Johnson from $165.00 to $160.00 and set a “neutral” rating for the company in a report on Wednesday, October 19th. Finally, Bank of America decreased their price objective on shares of Johnson & Johnson from $185.00 to $178.00 and set a “neutral” rating for the company in a report on Friday, October 14th. Seven analysts have rated the stock with a hold rating, five have assigned a buy rating and one has assigned a strong buy rating to the company. According to MarketBeat, the company has a consensus rating of “Moderate Buy” and an average price target of $181.75.

Johnson & Johnson Company Profile

(Get Rating)

Johnson & Johnson is a holding company, which engages in the research and development, manufacture and sale of products in the health care field. It operates through the following segments: Consumer Health, Pharmaceutical, and Medical Devices. The Consumer Health segment includes products used in the baby care, oral care, beauty, over-the-counter pharmaceutical, women’s health, and wound care markets.